PMID- 1890164
OWN - NLM
STAT- MEDLINE
DCOM- 19911011
LR  - 20190918
IS  - 0271-9142 (Print)
IS  - 0271-9142 (Linking)
VI  - 11
IP  - 3
DP  - 1991 May
TI  - Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) 
      envelope synthetic peptides in HTLV-I-infected individuals.
PG  - 143-51
AB  - HTLV-I (human T-cell lymphotropic virus type I) is the retrovirus related to two 
      distinct diseases, adult T-cell leukemia/lymphoma (ATLL) and HTLV-I-associated 
      myelopathy (HAM). We analyzed the difference in antibody activities against the 
      viral protein and the difference in specificities of anti-HTLV-I envelope 
      antibodies among HTLV-I-infected individuals from the same HTLV-I-endemic area 
      using a HTLV-I-gag-env hybrid protein and HTLV-I-env-encoded synthetic peptides 
      as antigens, respectively. The difference in the responses of IgG anti-HTLV-I 
      envelope antibody production among HTLV-I-infected individuals was qualitative as 
      well as quantitative. Sera from patients with HAM showed significantly higher 
      activities of antibodies against HTLV-I-gag-env hybrid protein than sera from 
      other HTLV-I-infected individuals including ATLL patients. The specificities of 
      IgG anti-HTLV-I-envelope antibodies, tested on seven synthetic envelope peptides, 
      were directed mainly against four sites, V1E7 (residues 97-111), V1E8 (191-209), 
      and V1E9 (268-286) on gp46 and V1E1 (342-363) on gp21. Three of these sites were 
      shown to be immunodominant T-cell sites in mice in our previous study. Whereas 
      patients in all categories made antibodies specific for V1E1 and V1E8, only HAM 
      patients made antibodies to the V1E7 and V1E9 epitopes, suggesting a qualitative 
      difference in response. Whether this difference is of pathogenetic significance 
      is not clear.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Ida, H
AU  - Ida H
AD  - First Department of Internal Medicine, Nagasaki University School of Medicine, 
      Japan.
FAU - Kurata, A
AU  - Kurata A
FAU - Eguchi, K
AU  - Eguchi K
FAU - Kawakami, A
AU  - Kawakami A
FAU - Migita, K
AU  - Migita K
FAU - Fukuda, T
AU  - Fukuda T
FAU - Nakamura, T
AU  - Nakamura T
FAU - Kusumoto, Y
AU  - Kusumoto Y
FAU - Berzofsky, J A
AU  - Berzofsky JA
FAU - Nagataki, S
AU  - Nagataki S
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Antibodies, Viral)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Viral Envelope Proteins)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antibodies, Viral/biosynthesis
MH  - Antibody Specificity
MH  - B-Lymphocytes/*immunology
MH  - Carrier State/immunology
MH  - Female
MH  - HLA Antigens
MH  - HTLV-I Infections/*immunology
MH  - Human T-lymphotropic virus 1/*immunology
MH  - Humans
MH  - Immunoglobulin G/biosynthesis
MH  - Leukemia-Lymphoma, Adult T-Cell/immunology
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Paraparesis, Tropical Spastic/immunology
MH  - Recombinant Proteins/chemistry/immunology
MH  - Viral Envelope Proteins/chemistry/*immunology
EDAT- 1991/05/01 00:00
MHDA- 1991/05/01 00:01
CRDT- 1991/05/01 00:00
PHST- 1991/05/01 00:00 [pubmed]
PHST- 1991/05/01 00:01 [medline]
PHST- 1991/05/01 00:00 [entrez]
AID - 10.1007/BF00918682 [doi]
PST - ppublish
SO  - J Clin Immunol. 1991 May;11(3):143-51. doi: 10.1007/BF00918682.